<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05798260</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00101196</org_study_id>
    <nct_id>NCT05798260</nct_id>
  </id_info>
  <brief_title>T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19</brief_title>
  <official_title>Intensive Care Unit (ICU) Biospecimen and Data Repository</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      T-Cell Mitochondrial Respiration Response to Ketone monoester (Ketoneaid) in Healthy&#xD;
      Volunteers and COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2023</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Spare Respiratory Capacity (SRC)</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>This measurement indicates the capability of the cell to respond to an energetic demand as well as how closely the cell is to respiring to its theoretical maximum. The cell's ability to respond to demand can be an indicator of cell fitness or flexibility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal Respiration</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>Oxygen consumption used to meet cellular ATP demand resulting from mitochondrial proton leak. Shows energetic demand of the cell under baseline conditions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ATP production-coupled Respiration</measure>
    <time_frame>upon admission</time_frame>
    <description>The decrease in oxygen consumption rate upon injection of the ATP synthase inhibitor oligomycin represents the portion of basal respiration that was being used to drive ATP production. Shows ATP produced by the mitochondria that contributes to meeting the energetic needs of the cell.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal Respiration</measure>
    <time_frame>upon admission</time_frame>
    <description>The maximal oxygen consumption rate attained by adding the uncoupler FCCP. FCCP mimics a physiological &quot;energy demand&quot; by stimulating the respiratory chain to operate at maximum capacity, which causes rapid oxidation of substrates (sugars, fats, and amino acids) to meet this metabolic challenge. Shows the maximum rate of respiration that the cell can achieve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-Mitochondrial Respiration</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>Oxygen consumption that persists due to a subset of cellular enzymes that continue to consume oxygen after the addition of rotenone and antimycin A. This is important to get an accurate measure of mitochondrial respiration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Consumption Rate (OCR)</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>The oxygen consumption rate (OCR) of cells is an important indicator of normal cellular function. It is used as a parameter to study mitochondrial function as well as a marker of factors triggering the switch from healthy oxidative phosphorylation to aerobic glycolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extracellular acidification rate (ECAR)</measure>
    <time_frame>through study completion, an average of 2 months</time_frame>
    <description>Measuring the extracellular acidification rate (ECAR) provides a method for detection of glycolytic flux in T-cells in response to ketone mono ester</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>Healthy Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 positive admitted to the ICU and on the ventilator</arm_group_label>
    <description>COVID-19 positive admitted to the ICU and on the ventilator</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Agilent Seahorse XF Cell Mito Stress Test</intervention_name>
    <description>The Agilent Seahorse XF Cell Mito Stress Test measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells on the Seahorse XFe and XF Extracellular Flux Analyzers. It is a plate-based live cell assay that allows to monitor spare respiratory capacity (SRC), basal respiration, ATP production-coupled respiration, maximal respiration, and non-mitochondrial respiration in real time before and after ketone monoester</description>
    <arm_group_label>COVID-19 positive admitted to the ICU and on the ventilator</arm_group_label>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <other_name>Ketoneaid (Ketone monoester)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted at Duke Hospital Medical and Surgical ICU with COVID-19 manifested with&#xD;
        ARDS and on the ventilator&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        COVID-19 with ARDS and on the ventilator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  &lt;18 years&#xD;
&#xD;
          -  Steroid use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Barkauskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Director Duke Medical ICU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Molinger, MS</last_name>
    <phone>(919) 684-8111</phone>
    <email>jeroen.molinger@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zach healy, MD</last_name>
    <phone>(919) 684-8111</phone>
    <email>zachary.healy@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Christina Barkauskas</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Barkauskas, MD</last_name>
      <phone>919-684-8111</phone>
    </contact>
    <investigator>
      <last_name>Christina Barkauskas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zachery Healy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeroen Molinger, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 28, 2023</study_first_submitted>
  <study_first_submitted_qc>April 3, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 3, 2023</last_update_submitted>
  <last_update_submitted_qc>April 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitochondria</keyword>
  <keyword>ketone monoester</keyword>
  <keyword>seahorse</keyword>
  <keyword>ketoneaid</keyword>
  <keyword>SRC</keyword>
  <keyword>FCCP</keyword>
  <keyword>ECAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

